NHS England is finally rolling out fampridine, the first MS drug designed to boost walking ability—potentially helping 5,000 people annually. After years of being deemed too costly, the drug’s value is now recognized, offering hope to patients like Aysen Slack, who previously couldn’t afford it. A one-month trial determines eligibility; clinical trials show 40% of users saw meaningful mobility gains. Not a cure, but a lifeline—restoring independence, freedom, and the simple joy of movement.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
